VCP and non-small cell lung carcinoma: Thus, selectively inhibiting VCP’s functions can be developed as potent therapeutic strategy to control NSCLC growth and metastasis, which warrants further standardization in pre-clinical murine models to ensure tumor specific drug delivery.